| |
Accumetrics cordially invites you to an ESC Congress 2010 mini-satellite symposium
focusing on a rapidly evolving and exciting topic: assessing patient response to
antiplatelet therapies and its clinical impact on multiple patient populations.
In joining the panel-based presentation and discussion, attendees will:
- Gain an understanding of the current and future landscape of oral antiplatelet therapy
- Review emerging data on the clinical utility of platelet assessment
- Discuss antiplatelet therapy options for elective PCI patients
|
Program Agenda
|
|
Antiplatelet Therapy Landscape: 2010 and Beyond
Prof David Erlinge, MD, PhD, FESC (Chair)
Head, Dept of Cardiology Lund
Lund University Hospital, Sweden
|
|
The Rationale For Individualized Antiplatelet Therapy in Patients with ACS
Matthew J. Price, MD, FACC, FSCAI
Director, Cardiac Catheterization Laboratory, Scripps Clinic
Assistant Professor, Scripps Translational Science Institute
La Jolla, California, USA
|
|
Why Stop At ACS? Elective PCI Patients Receive Antiplatelet Therapy Too.
Marco Valgimigli, MD, PhD
Director of the Catheterization Laboratory, Cardiology Surgery Unit
Ferrara University Hospital, Italy
|
Sponsored by an educational grant from Accumetrics.
|
|
|